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Hypertension is a major public health problem amenable to 
treatment. Numerous large scale clinical trials have dem- 
onstrated that effective, sustained control of elevated arte- 
rial pressure to a level below 140/90 mm Hg results in 
reduced cardiovascular morbidity and mortality. Over the 
past 4 decades antihypertensive drug therapy has evolved 
from a stepwise, but physiologically rational, selection of 
agents to specific programs tailored to individualized ther- 
apy for specific clinical situations. This evolution has taken 
place because of a greater understanding of the pathophys- 
iology of hypertensive diseases, the development of new 
classes of antihypertensive agents that attack specific pres- 
sor mechanisms, and the ability to wed these concepts into 
a rational and specific therapeutic program. 
Thus, with the currently available spectrum of antihy- 
pertensive therapy, we are now able to select treatment for 
special patient populations utilizing a single agent and, 
therefore, we can protect the heart, brain and kidneys and 
maintain organ function without exacerbating associated 
diseases. These benefits are clear-cut and have resulted in 
many millions of patients becoming the beneficiaries of this 
transfer of careful, painstaking and purposeful investiga- 
tive experiences into clinical practice. 
(J Am Co11 Cardiol1989;14:1595-608) 
The introduction of indirect blood pressure measurement in 
the mid 19th century has permitted the later correlation with 
hypertensive diseases (1). Thus, over the past 150 years, a 
number of fundamental and clinical concepts 
elucidated, permitting a greater understanding of 
the pathophysiology of hypertensive diseases. 
These include a clearer understanding of pressor 
and depressor mechanisms that involve neuro- 
humoral, hormonal, cardiovascular and renal 
responses that control arterial pressure (2-6). 
Hence, a better comprehension of these mecha- 
nisms has enabled the purposeful development 
and application of several different classes of 
therapeutic agents that intercede in the re- 
sponses of these systems and ultimately correct 
mally elevated arterial pressure. 
have been 
regimens that have progressed from direct-acting smooth 
muscle relaxing vasodilators that require diuretics to protect 
against intravascular fluid expansion, to more specific 
agents that act on cardiovascular function through specific 
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mechanisms that control vascular smooth mus- 
cle tone and cardiac responses [e.g., alpha- or 
beta-adrenoreceptor inhibition, calcium antago- 
nism or angiotensin-converting enzyme inhibi- 
tion]. 
The evolution of these major classes of anti- 
hypertensive agents, their mechanisms of action 
and hemodynamic effects, as well as their rela- 
tions to specific cardiovascular risk factors are 
reviewed. Our discussion emphasizes their rela- 
:ific cardiovascular problems that are associated 
Over these past 40 years, the emergence of numerous 
therapeutic innovations and drug discoveries has resulted in 
better control of hypertensive disease (Table 1). With 
greater understanding of these new classes of agents, it was 
possible to regulate arterial pressure and develop therapeutic 
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Table 1. Evolutionary Use of Antihypertensive Drugs 
Drugs or Drug Classes Year* 
Ganglionic blocking agents (hexamethonium, trimethaphan, tetraethylammonium 
chloride, pentolinium tartrate) 
Rauwolfia and veratrum alkaloids (reserpine, cryptenamine tannate) 
Vasodilator (hydralazine) 
Alpha-adrenergic receptor blockers (phentolamine, phenoxybenzamine) 
Thiazide diuretics (chlorothiazide, hydrochlorothiazide) 
Post-ganglionic blocker (guanethidine) 
Potassium-sparing diuretics (spironolactone, amiloride, triamterene) 
Central alpha,-receptor agonist (methyldopa, clonidine) 
Beta-adrenergic receptor blockers (propranolol) 
Vasodilator (minoxidil) 
Peripheral alpha,-adrenergic receptor blocker (prazosin) 
Calcium channel antagonist (verapamil)t 
Angiotensin-converting enzyme inhibitor (captopril) 
Alpha-beta-adrenergic receptor blocker (labetalol) 
New investigational classes of drugs: 
Serotonergic receptor antagonists (ketanserin) 
Selective dopamine, antagonists (fenoldopam) 
Renin inhibitors 
Late 1940s 
1931 (India), 
1952 (United States) 
1951 
1954 
1957 
1959 
1958 to 1964 
1963 and 1974 
1964 (Europe), 
1974 (United States) 
1968 
1976 
1980 
1981 
1984 
1990s 
*Year approved for use as antihypertensive agent in the United States unless otherwise noted. Werapamil was 
synthesized and used for investigation as early as 1962 in Europe. 
Agents That Inhibit the Sympathetic 
Nervous System 
A number of neural mechanisms serve to modulate cir- 
culatory control of arterial pressure (6,7) including neural 
afferents in baroreceptors (or mechanoreceptors) located in 
arteries, veins and the heart (7). Signals from these receptors 
travel centrally to the medullary vasomotor centers of the 
brain and result in efferent reflexive cardiovascular re- 
sponses. These efferent impulses are conducted to the pe- 
riphery by means of sympathetic and parasympathetic nerve 
fibers to affect changes in vessel caliber, heart rate and 
myocardial contractility through the release of various neu- 
rohumoral substances (i.e., catecholamines, indoles and 
peptide hormones). The responses elicited by these impulses 
modulate cardiovascular and renal homeostatic regulation of 
arterial pressure (6-9). 
Therapeutic agents that modify neural input to the car- 
diovascular and renal systems were among the first intro- 
duced for the management of hypertensive diseases (9). 
Over the years, this array of compounds has permitted the 
possibility of virtual pharmacologic dissection of the entire 
autonomic nervous system. Thus, it is possible to select 
agents that inhibit outflow of impulses from various cardio- 
vascular control centers in the brain, ganglionic neurotrans- 
mission, release of neurohumoral substances from nerve 
endings, and alpha- or beta-adrenoreceptors, or both, on 
presynaptic nerve endings or at postsynaptic sites on cardiac 
and vascular smooth muscle cells (10,ll). 
Ganglionic Blockers 
This potent group of antihypertensive agents (e.g., hexa- 
methonium, trimethaphan) was synthesized in the late 1940s 
and was the first group used to treat hypertension (12,13). 
They inhibit the neurotransmission at the thoracolumbar 
ganglia by blocking the action of released acetylcholine to 
interfere with postganglionic neuronal propagation of the 
impulse (13). This results in reduced sympathetic tone as 
well as arterial and venodilation. The pressure fall is most 
pronounced with upright posture, as a result of peripheral 
blood pooling and reduced venous return to the heart (13). 
Declines in arterial pressure, therefore, result from a dimin- 
ished cardiac output, as well as reduced total peripheral 
resistance (13,14). Although these agents are less used 
today, they were responsible for the dramatic reversal of 
morbidity from malignant hypertension and other severe 
hypertensive complications in the early years of therapy 
(15). However, trimethaphan continues to be used for the 
management of certain hypertensive crises (e.g., dissecting 
aortic aneurysm) and for intraoperative control of arterial 
pressure (15,16). 
Postganglionic Adrenergic Inhibitors 
Reserpine. This agent was introduced in the mid 1950s 
and is still widely used throughout the world. It acts by 
depleting neurotransmitters (e.g., norepinephrine, epineph- 
rine, serotonin) from postganglionic nerve endings as well as 
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in the brain (11,17). As a result, arterial pressure and total 
peripheral resistance are reduced, heart rate slowed and 
cardiac output, as well as renal blood flow. maintained 
(1819). 
The Veterans Administration cooperative studies (20,21) 
supplied some of the first evidence that low doses of reser- 
pine (0.1 to 0.5 mg/day), in combination with a diuretic, 
effectively lower arterial pressure with relatively few side 
effects. Shortly thereafter, these landmark Veterans Admin- 
istration multicenter studies (22,23) demonstrated a dramatic 
reduction in cardiovascular morbidity and mortality as well 
as diminished progression of diseases associated with hyper- 
tension. Furthermore, studies (24-29) with a number of 
adrenergic inhibitors (e.g., the centrally acting agents and 
P-adrenoreceptor blockers) as well as angiotensin- 
converting enzyme inhibitors and calcium channel antago- 
nists have shown reversal of left ventricular hypertrophy, a 
known risk factor for myocardial infarction. Reserpine is 
less used today in this country because of the availability of 
other agents with less troublesome side effects. 
Guanethidine. This agent became available for manage- 
ment of hypertension in the late 1950s and remains one of the 
most potent sympatholytic drugs (30). It acts by depleting 
norepinephrine from the postganglionic nerve ending but, 
unlike reserpine, it has no central action (30-32). This results 
in a reduced total peripheral resistance and venous tone that 
permits a fall in arterial pressure, particularly with assump- 
tion of upright posture. When this drug is given intrave- 
nously, it produces a transient rise in arterial pressure 
secondary to catecholamine release (32,33). This increase in 
pressure may be attenuated by pretreatment with alpha- 
adrenergic receptor blocking drugs (11,32). 
Prolonged therapy with guanethidine results in a negative 
cardiac c-hronotropic and inotropic effect secondary to myo- 
cardiul catecholamine depletion (34). The reduced venous 
return results from peripheral venous pooling, accounting 
for the reduction in cardiac output and possible decrease in 
blood flow to major circulatory beds including the kidney 
(35). Furthermore. intravascular volume expansion attenu- 
ates its hypotensive effect, a problem that is resolved by the 
addition of a diuretic (36,37). 
Guanethidine has been used less frequently in recent 
years, even if hypertension is severe, primarily because of 
the availability of other potent and specific agents with fewer 
side effects. However, a congener of guanethidine, gua- 
nadrel, is used for the treatment of mild to moderate hyper- 
tension in less potent dosages. Nevertheless, its mechanism 
of action is similar to that of guanethidine. 
Peripheral Alpha-Adrenergic Inhibitors 
The first alpha-adrenoreceptor blocking agents used for 
hypertension were phentolamine and phenoxybenzamine 
(38). These agents inhibit norepinephrine stimulation of both 
postsynaptic (alpha,) and presynaptic (alpha,) adrenergic 
receptor sites. The major clinical indications for phentol- 
amine (an intravenous compound, or phenoxybenzamine 
(for oral use) are hypertensive states associated with cate- 
cholamine excess (e.g., pheochromocytoma, clonidine with- 
drawal) (38,393. These agents, like the foregoing adrenolytic 
agents, also re-expand intravascular (plasma) volume asso- 
ciated with pressure reduction. This action has been ex- 
ploited clinically in the preoperative preparation of patients 
with pheochromocytoma. These agents prevent intraopera- 
tive hypotension associated with tumor removal in these 
patients with catecholamine-induced volume contraction 
(39). These agents do not prevent cardiac arrhythmias asso- 
ciated with catecholamine excess, a problem that may be 
alleviated with beta-adrenoreceptor blockers (40). 
The more selective alpha,-receptor antagonists directly 
inhibit norepinephrine stimulation of these receptor sites on 
vascular smooth muscle without altering myocardial con- 
tractility, cardiac output or reflexively stimulating an in- 
crease in heart rate (41). This lack of reflex increase in heart 
rate, even with rapid pressure reduction following the first 
dose, has been attributed to direct alpha,-receptor inhibition 
at the cardiac myocyte (41-43). The clinical manifestations 
of the “first does phenomenon” (e.g., orthostatic hypoten- 
sion) may be minimized by initial administration of prazosin 
at bedtime. 
The alpha, adrenoreceptor inhibitors now include a num- 
ber of agents (i.e., prazosin, terazosin, doxazosin and in- 
dorumin), each of which dilates the arterioles, thus reducing 
arterial pressure (41,42). In addition to arterial pressure 
reduction. these agents have been used to treat patients with 
congestive heart failure. By virtue of their potential vasodi- 
lating effect on constricted peripheral venules, alpha,- 
adrenoreceptor blockers reduce cardiac preload as well as 
afterload. an effect not observed in patients with uncompli- 
cated hypertension (44). However, this beneficial effect on 
systemic hemodynamics, noted in early studies with pra- 
zosin. was not substantiated. Furthermore, long-term stud- 
ies in patients with heart failure demonstrated a tachyphy- 
lactic response with prolonged use of the drug (44). This 
response presumably is secondary to maximal alphai- 
adrenoreceptor blockade. Thus, the use of prazosin in 
patients with heart failure has diminished, although this may 
reflect the more recent introduction of the angiotensin- 
converting enzyme inhibitors. 
Centrally Active Alpha,-Receptor Agonists 
Clonidine. This drug, an imidazoline derivative, is a 
prototype of agents that stimulate central alpha,-receptors 
(45,46). It is related chemically to tolazoline and phentol- 
amine, although it has few direct peripheral vasodilating 
effects in therapeutic dosages (46). Clonidine acts by stimu- 
lating alphaz-receptors in the nucleus tractus solitarii of the 
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brain which, in turn, decrease central adrenergic outflow to 
the heart, vessels and kidney (47). Thus, the resultant fall in 
arterial pressure is not accompanied by reflex tachycardia 
(46,48). Interestingly, the hypotensive effect of central 
alpha, receptor agonists is attenuated in the presence of 
tricyclic antidepressant medications, a response that is ap- 
parently independent of the alpha,-receptor (49). 
With long-term treatment, clonidine decreases total pe- 
ripheral resistance in both supine and standing positions. 
Furthermore, cardiac output and oxygen consumption, in 
response to exercise, remain unchanged from pretreatment 
values (49). In addition, clonidine does not alter renal blood 
flow, glomerular filtration rate or renal sodium handling; 
however, renin release is suppressed (50). 
Clonidine acts promptly and, when administered at 
hourly intervals, may be useful in treating hypertensive 
urgencies and emergencies (15). If clonidine is withdrawn 
abruptly, rebound hypertension may ensue, possibly leading 
to a hypertensive crisis (51). However, the newer and 
longer-acting agents (e.g., guanabenz, guanfacine) may not 
be associated with this adverse effect (52). Other side effects 
produced by clonidine and shared by all central alpha,- 
receptor agonists include drowsiness, dry mouth and im- 
paired sexual function (19,46). These problems may limit 
their clinical usefulness. 
Methyldopa. This agent is the other prototype of a cen- 
trally active alphal-receptor agonist. It was synthesized in 
the early 1950s and described as a dopa-decarboxylase 
inhibitor (53). Later, false neurohumoral transmission (54) 
and other antihypertensive mechanisms including direct 
inhibition of central vasomotor centers (55) and renal sup- 
pression of renin release (56) were suggested. At present it 
appears to act similarly to clonidine, although it must be 
initially metabolized in the nuclei tractus solitarii neurons to 
alpha-methyl-norepinephrine, the direct central alpha,- 
receptor agonist (57). 
Hemodynamically, methyldopa acts promptly (within a 
few hours) to reduce arterial pressure through a slight 
decrease in cardiac output that is associated with a dimin- 
ished total peripheral resistance (58,59). This decline in 
output is transient and does not affect renal blood flow or 
glomerular filtration rate. Thus, renal function is preserved 
even in patients with renal insufficiency (10,60). In addition 
to the side effects described for clonidine, hepatocellular 
dysfunction and a Coombs’ test positive for hemolytic 
anemia have been reported with methyldopa administration 
(10,11,19). 
Beta-Adrenergic Receptor Antagonists 
Pronethalol was the first beta-adrenoreceptor blocker 
synthesized (61), but it was not used clinically because of 
adverse effects. Shortly thereafter, propranolol, a beta,- and 
beta,-adrenoreceptor blocker, was introduced for the treat- 
ment of angina pectoris and hypertension (62). Since then, 
many other compounds have been introduced, including 
agents that are more water-soluble (nadolol, atenolol) 
(63,64); agents with intrinsic sympathomimetic activity (ox- 
yprenolol, pindolol, acebutolol) (65,66); and those with some 
degree of cardioselectivity (atenolol, metoprolol, acebutolol) 
(64,66-68). Notwithstanding these varied characteristics, in 
the dosages employed for the treatment of hypertension and 
angina pectoris, their more receptor-specific actions appear 
to have little variance. Despite their widespread use over the 
past 25 years, their antihypertensive action remains unre- 
solved. However, a number of mechanisms have been 
postulated, including a decreased cardiac output (69), reset- 
ting of arterial baroreceptors (70), reduction in circulating 
plasma renin activity (71), central adrenoreceptor stimula- 
tion (19,72) and peripheral alteration of catecholamine re- 
lease (73). 
Hemodynamically, the beta-adrenoreceptor inhibitors 
decrease heart rate, cardiac output and myocardial oxygen 
consumption and increase total peripheral resistance 
(66,69). Conversely, renal blood flow and glomerular filtra- 
tion rate are maintained despite reductions in cardiac output 
in the supine position (66). However, studies (74) examining 
the renal effects of propranolol demonstrate that quiet stand- 
ing significantly decreases renal blood flow and results in 
avid sodium retention in normal and hypertensive subjects. 
Whereas these agents are useful in patients with uncompli- 
cated essential hypertension and ischemic heart disease, 
their cardiac and renal hemodynamic effects and other 
metabolic effects may preclude their use in patients with 
other conditions (e.g., diabetes mellitus, congestive heart 
failure, pulmonary disease, peripheral arterial insufficiency). 
These agents may also have adverse effects on lipid 
profiles (75,76), and some studies have shown that nonspe- 
cific beta-blockers increase triglycerides and decrease the 
ratio of high density lipoprotein (HDL) to low density 
lipoprotein (LDL) cholesterol. No such adverse effects on 
HDLlLDL cholesterol ratios have been shown with agents 
having intrinsic sympathomimetic activity (76). Neverthe- 
less, a number of large scale, double-blind, prospective trials 
(77-84) with beta-adrenoreceptor blockers clearly demon- 
strate both a reduction in cardiovascular morbidity and 
mortality and improved myocardial preservation. Thus, 
these agents serve to protect patients with prior myocardial 
infarction from increased myocardial oxygen demands and 
high circulating catecholamines, factors that contribute to 
cardiac arrhythmias in this setting. Furthermore, these 
agents diminish the mass of the hypertrophied left ventricle 
(85) and lessen symptoms from angina pectoris (86). 
Several studies have compared the efects of the thiazide 
diuretics with the beta-blockers (most notably, propranolol) 
(77,80,82,84). Trials conducted by the Medical Research 
Council and the Australian Mild Hypertension Group (77,79) 
demonstrated that the thiazide diuretics protected hyperten- 
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sive patients who were smokers from subsequent stroke 
better than propranolol, even though the two agents were 
equally efficacious in controlling arterial pressure. At 
present, there is no available explanation for this finding. 
Combined Alpha- and Beta-Blocker 
Labetalol combines (within the same molecule) nonselec- 
tive beta-adrenoreceptor, as well as alpha,-receptor inhibi- 
tory properties. This agent lowers arterial pressure by re- 
ducing total peripheral resistance without changing resting 
heart rate or cardiac output (87,88). Thus, when adminis- 
tered intravenously, arterial pressure falls promptly without 
the reflex stimulation of the heart (88). Hence, this agent is 
useful in patients with hypertension and other concomitant 
problems (i.e., symptomatic coronary artery disease, con- 
gestive heart failure or hypertensive emergencies with and 
without dissecting aneurysm) (89). 
Diuretics 
Repeated studies have demonstrated that the prevalence 
of hypertension in any particular culture is directly related to 
the dietary sodium intake of those populations (90). More- 
over, in cultures in which ~60 mEq of sodium is consumed 
daily, arterial pressure does not increase with aging and 
hypertension is virtually nonexistent. In contrast, hyperten- 
sion is highly prevalent in those industrialized societies in 
which sodium intake is higher (90,91). Diuretics seem to 
offset these effects by their natriuretic action and diuretics, 
when employed as single agents for the management of 
hypertension, have been effective for over 30 years (92). 
Several mechanisms have been proposed for their anti- 
hypertensive action including 1) intravascular volume con- 
traction; 2) reduced vascular responsiveness to naturally 
occurring vasoconstrictor substances and enhanced respon- 
siveness to depressor substances; 3) decreased sodium con- 
tent of the arterial wall; 4) altered transmembrane ionic 
exchange; 5) diminished baroreceptor activity; 6) induction 
of local tissue dilators (e.g., kinins, prostacylins) in the 
arterial wall; and 7) a direct vasodilating action on the 
arteriole (92,93). 
Hemodynamic effects. The initial hemodynamic effect of 
diuretics relates to a decreased cardiac output in response to 
intravascular volume contraction produced by diuresis (92). 
However, within several weeks plasma volume and cardiac 
output return toward pretreatment levels and total peripheral 
resistance decreases. Thus, the net long-term hemodynamic 
effect of diuretic therapy is reduced total peripheral resis- 
tance, with minimal decreases in plasma and extracellular 
fluid volumes. Diuretics also induce a sustained rise in 
plasma renin activity and when therapy is stopped (even 
after several years), plasma volume expands and plasma 
renin activity decreases (92,93). This effect has been em- 
ployed in treating patients with low renin essential hyperten- 
sion in order to optimize conditions for angiotensin- 
converting enzyme inhibitors (94). 
Clinical trials. Most of the major clinical trials have 
employed diuretics for initial monotherapy of essential hy- 
pertension, and, more recently, the Systolic Hypertension in 
the Elderly Program has used them for the treatment of 
isolated systolic hypertension (95). Moreover, the European 
Working Party Trial for Hypertension in the Elderly (80) and 
the Medical Research Council trial (77) have reaffirmed the 
safety and efficacy of these agents for the treatment of 
diastolic hypertension in elderly patients. Thus, the diuretics 
continue to be recommended as one of four major classes of 
therapeutic agents for first-line antihypertensive therapy 
(96). 
Side effects. Diuretics have important metabolic side ef- 
fects that may limit their use in other clinical conditions 
(e.g., hypokalemia, diabetes mellitus. hyperlipidemia, renal 
diseases, gout) (11,81). Hypokalemia has been implicated in 
the MRFIT study (81) as a possible factor in the sudden 
death of patients with cardiac involvement. As a result, the 
Joint National Committee (96) recommended reduced dos- 
ages of diuretics for pressure control because they are 
equally effective and induce less disturbing hypokalemia. 
Moreover, sodium restriction in patients treated with diuret- 
ics will diminish potassium wastage abetted by the induced 
hyperaldosteronism. Therefore, it seems reasonable to ad- 
minister lower doses of the thiazide diuretics (e.g., 12.5 to 25 
mg hydrochlorothiazide) and, if necessary. to prescribe a 
potassium-sparing agent (spironolactone, triamterene or 
amiloride) to protect patients with left ventricular hypertro- 
phy, cardiac failure, digitalis therapy or chronic diarrhea 
from further ventricular irritability resulting from hypokale- 
mia (96). 
Angiotensin-Converting Enzyme Inhibitors 
Mechanism of action. The first angiotensin-converting 
enzyme inhibitor was developed in the 1970s and introduced 
in the early 1980s for the treatment of hypertension (Table 
I). These agents have emerged over the past 10 years as a 
major therapeutic option for the initial treatment of hyper- 
tension (97-100). They inhibit the conversion of angiotensin 
I to angiotensin II; they also inactivate circulating bradyki- 
nin. a potent naturally occurring vasodilating agent. Further- 
more, they interfere with the interaction of angiotensin II 
with norepinephrine and with local tissue prostacyclin. They 
also reduce the formation of the heptapetide, angiotensin III, 
which ultimately stimulates the adrenal cortical synthesis of 
aldosterone, thus decreasing a known sodium-retaining hor- 
mone (97). Hemodynamically, these agents lower arterial 
pressure by reducing total peripheral resistance without 
increasing heart rate, cardiac output or myocardial contrac- 
tility. Renal blood flow may increase without altering glo- 
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merular filtration rate, thereby reducing the glomerular fil- 
tration rate (100,101). 
Clinical effects. In a multicenter study (lOl), captopril(50 
to 75 mg daily) controlled arterial pressure in patients with 
mild to moderate hypertension and was as effective as 
hydrochlorothiazide (50 mg/day) (99,101,102). Captopril, 
enalapril and lisinopril are equally effective in reducing 
arterial pressure in patients with hypertension, and they 
have a low side effect profile. Nevertheless, they should be 
used with extreme caution in patients with renal functional 
impairment and in patients receiving potassium supplements 
or potassium-sparing agents. These agents may lead to hyper- 
kalemia by either exacerbating renal insufficiency or inhibit- 
ing aldosterone production (103,104). They should not be 
administered to patients with bilateral renal artery disease or 
with arterial disease of solitary kidneys because renal failure 
and malignant hypertension may be produced (105-107). 
Angiotensin-coverting enzyme inhibitors are particularly 
effective in hypertensive patients with high plasma renin 
activity states including congestive heart failure. These 
agents are also effective in patients with normal or low 
plasma renin activity and in anephric individuals, presum- 
ably because of the pressure of the renin-angiotensin system 
in vascular smooth muscle, myocardial and other extrarenal 
cells (97). Because of their beneficial renal hemodynamic 
effects, they are useful in patients with diabetes mellitus and 
with collagen vascular diseases (101,103). 
Calcium Channel Antagonists 
These agents represent another new class of antihyper- 
tensive compounds. Verapamil was the first to be synthe- 
sized (in the late 195Os), but was not made available for 
treatment of hypertension in the United States for almost 30 
years. At present, a large number of such compounds have 
been released for treatment of hypertension and heart dis- 
ease including nifedipine, diltiazem, nicardipine, isradipine, 
nitrendipine and others (96). Although all these agents are 
classed as calcium channel antagonists, they differ greatly 
with respect to chemical structure, physiologic action, and 
cardiovascular and renal hemodynamic problems. 
Mechanism of action. Vasoconstriction, myocardial con- 
tractility and cardiac automaticity all depend on transmem- 
brane calcium fluxes, and in these cells altered permeability 
of the calcium ion results in changes in vessel caliber and 
cardiac function (108-l 11). Therefore, calcium channel antag- 
onists reduce intracellular influx of calcium, which results in 
reduced binding to the calmodulin, thus reducing contraction. 
The calcium antagonists all produce arteriolar dilation 
and reduce arterial pressure with variable effects on cardiac 
output and myocardial contractility. Verapamil alters heart 
rate conduction, whereas nifedipine reflexively increases 
heart rate. Diltiazem has little effect on heart rate and 
depresses myocardial contractibility less than verapamil. 
Clinical effects. In general, most studies have revealed 
that the calcium antagonists are as effective as the other 
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classes of agents for reducing arterial pressure. They do so 
while maintaining an unchanged ‘cardiac output and renal 
blood flow, as total peripheral and organ vascular resistances 
decrease (112-l 14). However, diltiazem increases renal 
blood flow while maintaining glomerular filtration rate by 
dilating efferent glomerular arteriolar resistance and, there- 
fore, glomerular hydrostatic pressure (115). 
The side effects of the calcium antagonists are minimal. 
The most frequent side effect of verapamil is constipation; 
diltiazem and nifedipine produce edema, and nifedipine also 
produces headache, flushing and dizziness (112,113). 
Direct-Acting Vasodilators 
Hydralazine. This drug was one of the first antihyperten- 
sive agents to produce arteriolar dilation and decreased total 
peripheral resistance through direct action on arteriolar 
smooth muscle (116,117). Many studies (118,119) have at- 
tested to the efficacy of hydralazine in lowering arterial 
pressure, but its principal clinical usefulness has been as an 
adjunct with other therapies rather than as a single agent 
(120,121). In the Veterans Administration cooperative study 
(22), hydralazine produced an additional decrease in mean 
arterial pressure of 7 mm Hg after the addition of hydrochlo- 
rothiazide. Several other studies (122,123), including another 
Veterans Administration study, showed that the thiazide- 
hydralazine combination produced a mean decrease of an 
additional 11 mm Hg in patients with mild to moderate 
hypertension. 
The usefulness of hydralazine is limited by several side 
effects, which include reflex sympathetic stimulation and 
tachycardia (124). This increase in heart rate that generally 
accompanies hydralazine has been associated with precipi- 
tation of myocardial infarction in high risk patients (123). It 
does not affect plasma lipids or glucose adversely. However, 
it may increase antinuclear antibody titer consistent with a 
diagnosis of lupus erythematosus, hepatitis and peripheral 
neuropathy (123,125,126) in a dose-related fashion. 
Minoxidil. This agent was initially synthesized in 1965; 
however, it was not approved for use as an antihypertensive 
agent until 1980 (Table 1). It is a potent vasodilator that acts 
as a direct arteriolar smooth muscle agent, thus reducing 
total peripheral resistance without modifying the sympa- 
thetic nervous system responses or increasing venous capac- 
itance (127). Early studies (127,128) demonstrated its effec- 
tiveness in combination with propranolol in patients with 
refractory hypertension, and it has been particularly useful 
in severely hypertensive patients with chronic renal failure 
receiving hemodialysis. The limitations of minoxidil are 
marked sodium and water retention, edema, pulmonary 
hypertension and hirsutism (129,130). Pericardial effusions, 
angina pectoris and lupus reactions have been associated 
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with minoxidi1(11,130,131). Therefore, minoxidil should not 
be used as a single agent, and it should be reserved for 
patients with refractory hypertension who have failed triple 
drug therapy. 
Miscellaneous New Compounds 
Several new and unique compounds have been synthe- 
sized to examine the pathophysiologic alterations in hyper- 
tension and include agents that antagonize serotonin, the 
statine substituted peptides that inhibit renin, and selective 
dopaminei-receptor antagonists (132-137). 
Ketanserin is a selective (S,) serotonergic antagonist 
with additional alpha, adrenoreceptor blocking properties. 
The interaction between the two receptors seems to be 
necessary for its antihypertensive action (132,133). After the 
intravenous administration of ketanserin, arterial pressure 
decreases with minimal associated cardiovascular reflexive 
changes, and several studies (132,133) have shown greater 
efficacy in elderly, rather than younger, patients. Its major 
side effects include dizziness, somnolence and dry mouth, 
similar to those commonly observed with the centrally acting 
alpha,-agonists. 
The renin inhibitors are peptides with an unusual amino 
acid, statine, in their structures. These agents inhibit human 
renin and seem promising for the management of hyperten- 
sion and as a physiologic probe. Although most studies have 
been performed in primates and animals with experimental 
hypertension (134,135), these agents have also been given to 
humans. Oral administration to conscious sodium-depleted 
marmosets resulted in significant blood pressure reduction 
secondary to complete inhibition of plasma renin activity. 
Dopamine infusion increases arterial pressure, but infu- 
sion of a selective dopamine, agonist (fenoldopam) reduces 
arterial pressure while increasing renal blood flow and 
sodium excretion (136,137). Studies in humans have docu- 
mented that by selective dopamine,-receptor stimulation, 
arterial pressure is decreased through a reduction in total 
peripheral resistance with associated reflex cardiovascular 
stimulation (136,137). 
A Perspective on the Treatment of 
Arterial Hypertension 
The Veterans Administration cooperative studies (96) 
over the past 30 years have clearly demonstrated a reduced 
morbidity and mortality with adequate control of arterial 
pressure. These initial multicenter studies were followed by 
numerous large scale clinical trials (138,139) involving 
>50,000 patients, all of which confirmed the initial observa- 
tion. In the earlier studies, a diuretic agent was prescribed 
initially and, if necessary, an antiadrenergic agent (e.g., 
reserpine, methyldopa, beta-blocker) was added, followed 
by a direct-acting smooth muscle vasodilator (i.e., hydrala- 
zine). This stepped-care approach was not only physiologi- 
cally rational, but also empirically sound. The diuretic was 
added first to prevent pseudotolerance of the expansion of 
intravascular volume with the second and third step agents 
(36,37). More recently other classes of antihypertensive 
agents were introduced and found to be as efficacious as 
“first step” therapy. These include the beta-adrenoreceptor 
inhibitors, calcium antagonists and the angiotensin- 
converting enzyme inhibitors (36,37,63,66,101,112-114). 
Thus, all four classes of compounds reduce pressure without 
intravascular volume expansion. Moreover, continued use 
of these agents has provided considerable insight into their 
efficacy. with concomitant diseases frequently encountered 
in patients with hypertension. With this additional informa- 
tion, it has now become possible to tailor a therapeutic 
regimen for individual patients, especially those with multi- 
ple diseases in whom one agent may serve the purpose of 
treating more than one disease. 
Coronary Artery Disease 
Ischemic heart disease is usually associated with arterial 
spasm or atherosclerotic occlusive disease of the coronary 
arteries. Patients with hypertension and coronary artery 
disease have increased myocardial tension and myocardial 
oxygen demands on the basis of the elevated pressure and 
increased cardiac size; these may be aggravated by the 
restricted blood flow offered by coronary artery disease (86). 
Thus, an ideal therapeutic agent in these patients would be 
one that improves coronary circulation, decreases pressure 
overload imposed on the left ventricle and reduces myocar- 
dial oxygen demand. 
Beta-adrenergic blockers. Coronary artery disease is a 
major cause of death in the United States, and hypertension 
is among its leading treatable risk factors (140). Many studies 
investigating the interrelation between hypertension and 
other risk factors associated with the development of coro- 
nary artery disease utilized a variety of antihypertensive 
agents to demonstrate that reduction of arterial pressure 
reduced overall morbidity and mortality (20-23,77-84, 
138,139). Beta-adrenoreceptor blocking agents were used in 
many of these studies (78-84). They have the advantage of 
reducing the “double product,” (i.e., the product of systolic 
pressure and heart rate), which is a major determinant of 
myocardial tension. Thus, these agents reduce myocardial 
oxygen demand and improve myocardial performance (25). 
The beta-adrenoreceptor blockers, because of their periph- 
eral vasoconstrictive effects, should be used with caution in 
patients with diffuse peripheral vascular disease. However, 
nadolol and atenolol have been shown to improve the renal 
circulation in patients with hypertension (63,64). 
Most beta-adrenoreceptor blockers adversely affect lipid 
profiles (e.g., decrease the HDL/LDL lipoprotein ratio). 
However, this ratio is not affected by beta-adrenoreceptor 
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antagonists with intrinsic sympathomimetic activity (75,76). 
These agents primarily increase the low density lipoprotein 
component in the blood, whereas others may have effects on 
triglyceride (76). 
Diuretics. Most large scale clinical trials (78-84) have 
also utilized diuretics alone or in combination with other 
agents for control of arterial hypertension in patients with 
coronary artery disease. Because these agents may produce 
various electrolyte and metabolic side effects (e.g., hy- 
pokalemia, hyperglycemia, increased cholesterol levels and 
hyperuricemia) (10,l I), it is possible that they might have 
attenuated their overall effectiveness in preventing myocar- 
dial infarction and sudden death (81,141). Hypokalemia 
associated with an abnormal electrocardiogram or with left 
ventricular hypertrophy may increase mortality of patients 
with coronary heart disease independent of its effect on 
blood pressure (81,142). Thus, patients using diuretics 
should have their serum potassium levels followed carefully 
(and corrected, if necessary) to prevent these problems. 
Moreover, if single-agent therapy is desired and hypercho- 
lesterolemia is of concern, it might be prudent to use an 
alternative single agent (e.g., a calcium antagonist or an 
angiotensin-converting enzyme inhibitor). These latter 
agents usually do not cause significant alterations in serum 
potassium, glucose, uric acid or lipids, each of which con- 
tributes to risk of coronary disease (98,143). 
Angiotensin-converting enzyme inhibitors and calcium 
channel blockers. The angiotensin-converting enzyme inhib- 
itors reduce total peripheral resistance without increasing 
heart rate and, therefore, serve to reduce myocardial and 
oxygen demand while maintaining renal blood flow (107, 
144). The calcium antagonists also attenuate the peripheral 
vasoconstrictor response to catecholamines and alter cal- 
cium influx into vascular smooth muscle, thereby reducing 
coronary artery spasm and myocardial oxygen demand while 
improving coronary blood flow (109-l 11,145). Furthermore, 
calcium antagonists have been shown in experimental stud- 
ies (146) to reduce atherogenesis, a major factor in the 
pathogenesis of coronary artery disease. Therefore, the 
optimal agents for treatment of hypertension in patients with 
coronary artery disease would be those groups of drugs that 
control arterial pressure without adversely affecting electro- 
lytes, plasma lipids or other metabolic processes, thereby 
improving myocardial oxygen demand and left ventricular 
afterload. Therefore, the calcium channel antagonists, an- 
giotensin-converting enzyme inhibitors and some of the beta- 
adrenoreceptor blockers would be optimal for such patients. 
Myocardial Infarction 
Role of antihypertensive agents. Hypertension has a pro- 
found, deleterious effect on the clinical course of patients 
with acute myocardial infarction or unstable angina pectoris 
(147). The elevated arterial pressure that results in increased 
ventricular afterload and outflow tract impedance also in- 
creases myocardial oxygen demand, further limiting ventric- 
ular function (86). Many studies (148,149,151) have shown 
that reduction of pressure, especially with agents that reduce 
myocardial oxygen consumption, preserve or improve myo- 
cardial function and reserve. Such agents reduce mortality 
after a myocardial infarction; they include the beta- 
adrenoreceptor blockers without intrinsic sympathomimetic 
activity and the calcium antagonist diltiazem in the patients 
with non-Q wave infarction (150,151). However, none of the 
calcium antagonists and only the beta-adrenoreceptor antag- 
onist timolol has been shown to limit infarct size or prevent 
myocardial infarction (148,152). Likewise, the angiotensin- 
converting enzyme inhibitors have not prevented reinfarc- 
tion of myocardium, although captopril, in preliminary trials 
(152-157) has been shown to protect the heart from devel- 
oping subsequent cardiac failure after myocardial infarction. 
This action of captopril in the postinfarction period has been 
attributed to the concept of “remodeling” of the myocar- 
dium; however, the mechanism is unclear. As a group, 
angiotensin-converting enzyme inhibitors are beneficial in 
these patients because they reduce total peripheral resis- 
tance and myocardial oxygen demand without increasing 
heart rate in the postmyocardial infarction period (153). 
Clearly, arterial pressure control by venodilation with 
nitrates and other antihypertensive agents relieves symp- 
toms of coronary ischemia. However, in contrast to the 
aforementioned drugs, agents such as nitroprusside and 
nitroglycerin, while reducing pressure and improving coro- 
nary blood flow, also increase heart rate and myocardial 
oxygen demand (148). Thus, drugs that reduce myocardial 
oxygen demand, improve pump function and diminish end- 
diastolic volume and myocardial tension are preferred in this 
clinical setting. 
Risk of excessive blood pressure reduction. Finally, recent 
reports have suggested that patients with hypertension who 
are treated vigorously with antihypertensive agents and 
whose diastolic arterial pressures are reduced to levels ~90 
mm Hg may demonstrate a greater predisposition to myo- 
cardial infarction and increased death rate (84,158). This 
so-called J-shaped curve of cardiovascular morbidity and 
mortality has been explained variously by excessive reduc- 
tion of pressure and too-vigorous use of antihypertensive 
agents (159,160). An additional possibility is that these 
patients with greater pressure reduction initially had more 
severe hypertension and vascular disease and required the 
greater decrement of diastolic pressure. Clearly, this is an 
area of current controversy that demands clarification. 
Congestive Heart Failure 
Hypertension-induced heart failure. Approximately one- 
half million people develop congestive heart failure each 
year in the United States; hypertension is the major caus- 
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ative factor (161). In those patients with hypertension- 
induced left ventricular failure, the primary goal of therapy is 
to control pressure and ultimately reduce left ventricular 
pressure overload. Treatment involves the use of agents that 
diminish left ventricular preload and afterload as well as 
those that reestablish normal electrolyte balance by attenu- 
ating the effects of the secondary hyperaldosteronism (154, 
157). The angiotensin-converting enzyme inhibitors alone, or 
in conjunction with diuretics or digitalis, are particularly 
useful in this setting. 
Hormonal factors. Elevated plasma catecholamine levels 
have correlated with mortality in patients with congestive 
heart failure (162). However, other humoral pressor sub- 
stances, such as vasopressin and angiotensin II, are also 
elevated in cardiac failure (163). Pharmacologic agents that 
modify these hormonal actions would also improve myocar- 
dial function. 
Preferred therapeutic agents. Several studies have evalu- 
ated the role of calcium antagonists, angiotensin-converting 
enzyme inhibitors, beta-adrenoreceptor blockers, diuretics 
and vasodilators in improving ventricular function in pa- 
tients with congestive heart failure with or without hyper- 
tension (147,150,154,164,165). These studies have shown 
that these agents reduce mortality by ~50% in patients with 
New York Heart Association class I and II congestive heart 
failure. In addition, the angiotensin-converting enzyme in- 
hibitors were shown to have a beneficial effect in patients 
with New York Heart Association class IV congestive heart 
failure (154,155). However, these studies also demonstrated 
that the beta-adrenoreceptor blockers and calcium antago- 
nists are relatively contraindicated in patients with severe 
cardiac failure. 
Diuretic therapy in cardiac failure is fraught with the 
intrinsic danger of electrolyte and acid-base problems (spe- 
cifically, hypokalemia, hypomagnesemia and alkalosis) 
(81,140). The angiotensin-converting enzyme inhibitors will 
help circumvent this problem by permitting the use of lower 
doses of diuretics (94). Recent studies (166) have suggested 
that the shorter-acting angiotensin-converting enzyme inhib- 
itors might have an advantage over the longer-acting agents, 
possibly because of their effects on renal function in patients 
with heart failure. Thus, in patients with congestive heart 
failure, the angiotensin-converting enzyme inhibitors, and 
perhaps cautiously administered calcium channel blockers, 
are indicated for the control of arterial pressure. These 
agents would serve to complement the therapeutic armamen- 
tarium of diuretics, digitalis and nitrates. 
Mitral Valve Prolapse 
This problem has been related to a variety of causes 
ranging from myxomatous degeneration of the mitral valve 
leaflets to the functional creation of prolapse by enhanced 
myocardial contractility on the posterior valve leaflet (167). 
Hemodynamically, these effects may result in mitral regur- 
gitation, cardiac arrhythmias and chest discomfort. When 
hypertension is present, left ventricular hypertrophy may 
also occur. 
Agents that have been beneficial to relieve the symptoms 
associated with mitral valve prolapse, the altered function, 
as well as the elevated arterial pressure, include the beta- 
adrenoreceptor blocking agents or calcium antagonists (167). 
Hyperkinetic Heart Syndrome 
Many patients with hypertension, particularly young pa- 
tients with milder degree of severity of the disease, have a 
hyperdynamic circulation that is manifested by a higher 
cardiac output, faster heart rate, increased myocardial con- 
tractility and oxygen consumption and, in some, increased 
responsiveness to circulating catecholamines (168,169). The 
mechanism for the increase in cardiac output has been 
shown to be increased adrenergic function or enhanced 
beta-adrenoreceptor responsiveness. Clinically, these pa- 
tients complain of palpitation, extra heartbeats and tachy- 
cardia; sometimes their symptoms are reproducible or ag- 
gravated by isoproterenol infusion (170). The beta- 
adrenoreceptor blocking agents appear to provide the best 
treatment for these patients. However, if they are contrain- 
dicated because of other preexisting medical conditions, 
other adrenergic inhibitors or the calcium antagonists may 
serve as an alternative therapy. 
Left Ventricular Hypertrophy 
Several studies (171-173) have shown that left ventricular 
hypertrophy, as assessed by echocardiography, is common 
in patients with hypertension. This hypertrophy is an inde- 
pendent risk factor for cardiovascular morbidity and mortal- 
ity (142,172,173). Because the increased geometry of left 
ventricle is a major determinant of ventricular tension, this 
factor (and the increased intraventricular systolic pressure) 
may explain some of this risk (86). Left ventricular hyper- 
trophy impairs coronary artery blood flow, which leads to a 
relative coronary ischemia in the presence of atherosclerotic 
occlusive coronary disease, a process further exacerbated 
by hypertension (85,86). Thus, control of arterial pressure 
will reduce myocardial oxygen consumption and help poten- 
tiate regression of left ventricular hypertrophy (24,25). 
Agents to reduce left ventricular mass. Most agents that 
reduce arterial pressure and maintain that reduction for a 
long period of time will decrease left ventricular mass, 
although minoxidil may actually increase left ventricular 
mass despite regulation of arterial pressure (174). Of the 
agents that diminish left ventricular mass, some have been 
shown experimentally and clinically to work faster than 
others (175,176). Thus, within 3 weeks experimentally, and 
from 4 to 12 weeks clinically, the centrally active adrenergic 
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inhibitors, the angiotensin-converting enzyme inhibitors and 
calcium antagonists reduce left ventricular mass (25-29). 
The mechanisms by which these drugs seem to diminish 
left ventricular mass is unknown; however, they seem to 
involve nonhemodynamic, as well as hemodynamic, factors 
(176). Methyldopa is the protype of the centrally acting 
agents (27-29). Clonidine does not reduce mass unless the 
dose providing hemodynamic effects equivalent to those of 
methyldopa is tripled; then it acts as a peripheral alpha- 
adrenergic receptor agonist to increase pressure and total 
peripheral resistance (28). In addition to this intriguing 
hemodynamiclnonhemodynamic dissociation is the finding 
that methyldopa reduces the mass of the nonhypertrophied 
left ventricle of normontensive rats, as well as of the 
nonhypertrophied right ventricle (28,177). The angiotensin- 
converting enzyme inhibitors and calcium antagonists also 
reduced left ventricular mass in experimental as well as 
clinical hypertension (97,111-114,175,176,178,179). They do 
not decrease right ventricular mass, although some angioten- 
sin-converting enzyme inhibitors may also diminish the mass 
of the nonhypertrophied normotensive rat left ventricle 
(178). 
Clinical effects. Clinical studies have yet to demonstrate 
the record of risk from regression of left ventricular hyper- 
trophy, although a preliminary report from the Framingham 
Heart Study (180) supplies some data. Still to be demon- 
strated is the lessening of risk with reversal of ventricular 
hypertrophy independent of arterial pressure control. More- 
over, there are no clinical studies showing improved func- 
tion of the left ventricle with pharmacologically reduced 
mass. Methyldopa (177) and captopri1(181), in fact, induced 
no improvement or even caused deterioration of left ventric- 
ular pumping ability at normal or elevated arterial pressures. 
Clearly, this is an active area of study and new and exciting 
information will undoubtedly be forthcoming in the near 
future. 
bate symptoms of claudication by their peripheral vasocon- 
stricting effect (66). 
Dissecting aortic aneurysm. Antihypertensive drugs that 
should be selected to manage patients with dissecting aortic 
aneurysm should decrease arterial pressure without reflex- 
ively increasing the shearing forces on the aortic wall 
(11,15). From among these, the ganglionic blocker tri- 
methaphan, the alpha-/beta-adrenoreceptor blocking agent 
labetalol possibly the angiotensin-converting enzyme inhib- 
itor, enalaprilat and sodium nitroprusside are those that 
satisfy these criteria. The vasodilators hydralazine and dia- 
zoxide are contraindicated unless there is preexisting pro- 
tection with a beta-adrenoreceptor blocking drug (11,15). 
Conclusions. Because of these recent advances in our 
understanding of the pathophysiology and pharmacology of 
hypertension, management of this disease should no longer 
be considered as empiric. The clinician now has the oppor- 
tunity to prescribe therapy that not only will control arterial 
pressure and provide benefit to the heart, kidneys and other 
organs, but also can be selected so that it will not exacerbate 
concomitant diseases (e.g., gout, diabetes, hyperlipidemia) 
or create new problems. Moreover, with continuing ad- 
vances and with new focus on the molecular mechanisms of 
disease and in designing new therapy (e.g., renin inhibitors), 
enlightened insights into the pathophysiology of the disease 
and more specific therapy will no doubt ensue. These past 4 
decades have been exciting and satisfying; those ahead will 
no doubt be astounding. 
We extend our gratitude and appreciation to Peggy Bourque for excellent 
secretarial assistance in typing this manuscript. 
Peripheral Vascular Disease 
Role of antihypertensive agents. The most common dis- 
eases of the aorta and peripheral vessels are aneurysms and 
occlusive arterial disease (182). They are more frequently 
seen in patients with diabetes mellitus, hyperlipidemia or 
hypertension, or combinations (182,183). Cigarette smoking 
significantly increases the probability of occlusive arterial 
disease in such patients (183). Although it would seem that 
agents that control elevated arterial pressure should improve 
peripheral vascular disease, until recently this had not been 
demonstrated. Agents such as calcium antagonists, an- 
giotensin-converting enzyme inhibitors, and alphai- 
adrenoreceptor blockers, which do not exacerbate symp- 
toms of peripheral arterial insufficiency, have been useful in 
controlling arterial pressure in these patients. Conversely, 
beta-adrenoreceptor blockers would be expected to exacer- 
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